Conference Call and Webcast Today at 8:30 a.m. ET COVAXIN demonstrates 100% efficacy against severe COVID-19 disease (including hospitalization) Master File submitted for U.S. Food and Drug Administration review prior to a planned Emergency Use Authorization application for COVAXIN $100.0 million

OCU200, a transferrin-tumstatin fusion protein, demonstrates potential to treat DME, DR, and Wet-AMD OCU200 reduced neovascularization and damage to retina and demonstrated comparable/slightly improved activity to aflibercept in an animal disease model MALVERN, Pa., May 06, 2021 (GLOBE NEWSWIRE) --

MALVERN, Pa., May 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc.  (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a

COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variant Potential effectiveness against multiple variants reduces the possibility of mutant virus escape According to World Health Organization, the double mutant variant of SARS-CoV-2 has spread to at

MALVERN, Pa., April 28, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has closed the

MALVERN, Pa., April 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has entered into

Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the second dose in preventing COVID-19 in those without prior infection Demonstrates 70% efficacy against asymptomatic COVID-19 infections; indicates potential to significantly reduce virus transmission

MALVERN, Pa., April 14, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that John Paul (J.P.)

MALVERN, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at a

Conference Call and Webcast Today at 8:30 a.m. ET COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81% in Phase 3 interim results Emergency Use Authorization pathway with U.S. regulatory authorities in development for COVAXIN™ European Commission grants orphan medicinal product